Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Investing Activities: 2014-2025

Historic Cash from Investing Activities for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -$181.4 million.

  • ImmunityBio's Cash from Investing Activities fell 378.88% to -$181.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.5 million, marking a year-over-year decrease of 825.52%. This contributed to the annual value of -$12.2 million for FY2024, which is 59.81% up from last year.
  • ImmunityBio's Cash from Investing Activities amounted to -$181.4 million in Q3 2025, which was down 1,023.53% from -$16.1 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Cash from Investing Activities peaked at $116.7 million during Q2 2022, and registered a low of -$181.4 million during Q3 2025.
  • For the 3-year period, ImmunityBio's Cash from Investing Activities averaged around -$21.5 million, with its median value being -$8.6 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 1,926.40% in 2021, then soared by 1,012.33% in 2022.
  • Over the past 5 years, ImmunityBio's Cash from Investing Activities (Quarterly) stood at -$137.8 million in 2021, then skyrocketed by 86.29% to -$18.9 million in 2022, then surged by 111.90% to $2.2 million in 2023, then soared by 337.26% to $9.8 million in 2024, then plummeted by 378.88% to -$181.4 million in 2025.
  • Its last three reported values are -$181.4 million in Q3 2025, -$16.1 million for Q2 2025, and $4.1 million during Q1 2025.